Global U.s Bacterial Conjunctivitis Drugs Market - Size, Share, Analysis, Trends to 2024

1. Global U.s Bacterial Conjunctivitis Drugs Market - Future market size in the U.S. is expected to grow (2024) Persistence Market Research Global U.s Bacterial Conjunctivitis Drugs Market is expected to progress a market worth of USD 439.8 million in 2024 - Persistence Market Research Persistence Market Research 1

2. Global U.s Bacterial Conjunctivitis Drugs Market - Future market size in the U.S. is expected to grow (2024) Persistence Market Research Released New Market Report “The U.S Market Study on Bacterial Conjunctivitis Drugs - fluoroquinolones to be the Largest Segment by 2024” the bacterial conjunctivitis drugs market in the U.S. was valued at USD 473.3 million in 2013 and is estimated to reach a market worth of USD 439.8 million in 2024, at a CAGR of2.7%from 2012 to 2018 and (-3.73%) from 2018 to 2024. Conjunctivitis is an inflammation of the conjunctiva - the clear membrane that covers the outermost layer of an eye and the inner surface of eyelids. Conjunctivitis is segmented into three major categories: infective (viral and bacterial), allergic, and irritant (chemical). Bacterial conjunctivitis is one of the most commonly observed eye problems across all age groups, generally caused by bacteria such as Staphylococcus aureus, Moraxella lacunata, Haemophilus influenza, and others (e.g. Chlamydia trachomatis, Proteus mirabilis, etc.). As reported by Healio (specialty medical news and journal publisher), approximately 5 million acute bacterial conjunctivitis cases are reported in the U.S. each year. Thus, high prevalence of bacterial conjunctivitis in the country demands effective medications, thereby driving the growth of the bacterial conjunctivitis drugs market in the U.S.However, despite the increasing incidence of bacterial conjunctivitis, the overall bacterial conjunctivitis market in the U.S. is likely to witness negative growth due to the patent expirations of major blockbuster drugs such as Vigamox, Moxeza, Zymaxid, and Besivance in the next few years. Rise in ophthalmic bacterial infections is increasing the demand for antibacterial drugs in the U.S. According to a clinical study conducted by the scientists Amir A. Azari and Neal P. Barney, published in the Journal of the American Medical Association (JAMA) in 2013, bacterial conjunctivitis accounts for over 50% of the conjunctivitis cases in the U.S. It also quoted that the incidence of bacterial conjunctivitis was estimated to be 135 in 10,000 in a single study.These statistics indicate that the U.S. is witnessing high incidence of bacterial conjunctivitis, hence leading to increased demand for bacterial conjunctivitis drugs in the country. Fluoroquinolones, aminoglycosides, macrolides and other antibacterials such as bacitracin, doxycycline, and ceftriaxone collectively form the bacterial conjunctivitis market; among which fluoroquinolones dominate the bacterial conjunctivitis drugs market in the U.S. with a Persistence Market Research 2

3. Global U.s Bacterial Conjunctivitis Drugs Market - Future market size in the U.S. is expected to grow (2024) share of more than 70% in 2013. Fluoroquinolones are more widely prescribed as compared to other antibiotic drug classes for the treatment of bacterial conjunctivitis across the U.S. due to their higher efficacy against antibiotic-resistant bacterial strains and broad spectrum activity. However, the segment is expected to witness a significant decline in sales in the near future -from a CAGR of 4.9% from 2012 to 2018 to a CAGR of (-8.1%) from 2018 to 2024. Burgeoning influx of generic antibacterials as well as upcoming patent expiries of leading branded formulations such as Vigamox, Zymaxid, Moxeza, and Besivance are a few major factors that would adversely affect the growth of the segment. Interested in report: Please follow the below links to meet your requirements; Request for the Report Sample: http://www.persistencemarketresearch.com/samples/5192 View TOC (table of content), Figures and Tables of the Report: http://www.persistencemarketresearch.com/toc/5192 With the loss of patent exclusivity, generics would offer physicians a broad range of affordable medications to prescribe, thereby significantly reducing the overall size of the bacterial conjunctivitis drugs market in the U.S. Hence, the future market growth would be contingent on commercialization of novel drugs for new indications. However, it has been observed that although the incidence rate of bacterial conjunctivitis is moderate in the U.S., the risk of morbidity is less, due to which the novel product pipeline for bacterial conjunctivitis is weak/dry. At present, only a few novel compounds are under investigation in both preclinical and clinical settings for the treatment of bacterial conjunctivitis. For more info: http://www.persistencemarketresearch.com/contact-us.asp The U.S. bacterial conjunctivitis drugs market displays intense competitive rivalry among existing players, as currently the market is highly fragmented comprising both large and small pharmaceutical companies. Key players profiled in this study include organizations such as Actavis plc, Akorn, Inc., Bayer AG, F. Hoffmann-La Roche, Ltd., Merck & Co., Inc., Persistence Market Research 3

4. Global U.s Bacterial Conjunctivitis Drugs Market - Future market size in the U.S. is expected to grow (2024) Novartis AG, Perrigo Company plc, Pfizer, Inc., Santen Pharmaceutical Co., Ltd., and Valeant Pharmaceuticals International, Inc. The U.S. bacterial conjunctivitis drugs market is segmented as follows: U.S. Bacterial Conjunctivitis Drugs Market, by Drug Class Fluoroquinolones Ciprofloxacin • Ofloxacin • Levofloxacin • Moxifloxacin • Gatifloxacin • Besifloxacin • Aminoglycosides Tobramycin • Gentamycin • Macrolides Erythromycin • Azithromycin • Others U.S. Bacterial Conjunctivitis Drugs Market, Pipeline Assessment Vancomycin Ophthalmic Ointment • Early Stage (Phase I and Phase II trials) - Tabular Representation • Persistence Market Research 4

5. Global U.s Bacterial Conjunctivitis Drugs Market - Future market size in the U.S. is expected to grow (2024) Market History: Bacterial conjunctivitis is one of the common eye problems faced worldwide, usually caused by various bacterium such as Staphylococcus aureus, Streptococcus pneumonia, Moraxella lacunata, Haemophilus influenza, and others (for instance, Chlamydia trachomatis, Proteus mirabilis, etc.). These organisms cause conjunctivitis with a higher level of redness and could spread through hand to the eye or sexual contact. Generally, bacterial conjunctivitis is acute as well as self-limiting and does not lead to any major health problem. Moreover, the disease can be treated on its own, hence the exact estimate of epidemiology of this disease has not been studied or established in many countries including the developed markets such as the U.S.Antibiotics in the form of ointment or eye drops are prescribed by ophthalmologists and optometrists for treating bacterial conjunctivitis.Increasing the incidence of bacterial conjunctivitis is the major driver of the bacterial conjunctivitis drugs market in the U.S. The U.S. bacterial conjunctivitis drugs market has been segmented based on drug classes most commonly used for the respective treatment. Based on the same, the market has been segmented into fluoroquinolones, aminoglycosides, macrolides and others. Fluoroquinolones market for bacterial conjunctivitis has been further studied for ciprofloxacin, ofloxacin, levofloxacin, moxifloxacin, gatifloxacin and besifloxacin. Aminolgycosides are further segmented into tobramycin and gentamycin. Similarly, erythromycin and azithromycin together represent the macrolides segment. Other antibacterials segment cumulatively comprisesbacitracin, doxycycline, polymyxin, and fusidic acid used for the treatment of bacterial conjunctivitis. Among these drug classes, the fourth-generation fluoroquinolones emerged as the segment leader accounting for over 70% of the total U.S. bacterial conjunctivitis drugs market in 2013. Owing to their high efficacy against antibiotic-resistant bacterial strains and broad spectrum activity, fluoroquinolones were able to dominate the overall market in 2013. However, the market for fluoroquinolones is expected to decline due to the growing influx of generic formulations, growing prevalence of drug resistance bacterial strains, and imminent patent expirations of leading branded formulations such as Vigamox, Besivance, and Moxeza. According to a study published in the Journal of the American Medical Association (JAMA), the incidence rate of bacterial conjunctivitis in the U.S. was estimated to be 135 in 10,000 individuals. Furthermore, the article stated that the cost of treating bacterial conjunctivitis ranges from USD 377 million to USD 857 million annually in the U.S. It also quoted that majority of conjunctivitis patients are originally treated by primary care physicians rather than eye care professionals. Around 1% of all primary care office visits in the U.S. are related to conjunctivitis. Bacterial infestation is the second most common cause of infectious conjunctivitis and accounts for 50% to 75% cases among children. This pattern was observed more frequently from December 2012 to April 2013.Thus, potential incidence of bacterial conjunctivitis is one of Persistence Market Research 5

6. Global U.s Bacterial Conjunctivitis Drugs Market - Future market size in the U.S. is expected to grow (2024) the major drivers of the bacterial conjunctivitis drugs market in the U.S. However, increasing genericization of antibacterial drugs coupled with upcoming patent expirations,and such few prominent factors are weakening the growth of the market in the near future. Currently, the market is highly fragmented and competitive due to the involvement of both large and small pharmaceutical companies. Actavis plc (now Allergan plc), Akorn, Inc.,Bayer AG, F. Hoffmann-La Roche Ltd., Merck & Co., Inc., Novartis AG, Perrigo Company plc, Pfizer, Inc., Santen Pharmaceutical Co., Ltd., and Valeant Pharmaceuticals International, Inc.are the major players operating in the bacterial conjunctivitis drugs market in the U.S. During the course of this study it has been observed that majority of the players are focusing on expanding their geographical reach and distribution network through mergers and acquisitions as well as through collaborations with other potential organizations operating in this market. Persistence Market Research 6

7. Global U.s Bacterial Conjunctivitis Drugs Market - Future market size in the U.S. is expected to grow (2024) Table of Content Chapter 1 Preface 1.1 Report Description 1.2 Market Segmentation 1.3 Research Methodology 1.4 Assumptions Chapter 2 Executive Summary 2.1 Market Snapshot: U.S. Bacterial Conjunctivitis Drugs Market Chapter 3 U.S. Bacterial Conjunctivitis Drugs Market Overview 3.1 Market Dynamics and Overview 3.2 Incidence Rate of Bacterial Conjunctivitis in the U.S. 3.3 Market Drivers 3.3.1 Rising Incidence of Ophthalmic Bacterial Infection 3.3.2 Susceptibility Among Various Age Groups Ranging from Neonates to Geriatrics 3.4 Market Restraints 3.4.1 Increasing Genericization of Antibacterial Drugs Could Lead to a Crowded and Unprofitable Market 3.4.2 Upcoming Patent Expirations likely to Hinder Market Growth 3.4.3 Burgeoning Multi-Drug Resistant Bacterial Strains Expected To Hinder Market Growth 3.5 Market Opportunities 3.5.1 Implementation of Product Development Partnerships (PDPs) Business Models 3.5.2 Focus on Designing and Producing Combination Drug Products 3.6 Event Impact Assessment: U.S. Bacterial Conjunctivitis Market 3.7 Regulatory Framework 3.8 Patents and Patent Challenges: Overview 3.9 List of API Manufacturers 3.10 Key Discontinued Products: U.S. Bacterial Conjunctivitis Drugs Market 3.10.1 Oxytetracycline/Polymyxin B 3.10.2 Sulfisoxazole Ophthalmic 3.10.3 Phenylephrine/Sulfacetamide Sodium 3.10.4 Chloramphenicol Persistence Market Research 7

8. Global U.s Bacterial Conjunctivitis Drugs Market - Future market size in the U.S. is expected to grow (2024) 3.11 Market Attractiveness Analysis: U.S. Bacterial Conjunctivitis Drugs Market, by Drug Type 3.12 Market Share Analysis: U.S. Bacterial Conjunctivitis Drugs Market, by Key Players, 2013 (Value %) Chapter 4 U.S. Bacterial Conjunctivitis Drugs Market, by Drug Class 4.1 Overview 4.1.1 Recommended Dosages for Treatment of Bacterial Conjunctivitis 4.1.2 U.S. Bacterial Conjunctivitis Drugs Market Revenue, by Drug Class, 2012 – 2024 (USD Million) 4.2 Fluoroquinolones 4.2.1 Fluoroquinolones for Bacterial Conjunctivitis Market Revenue, by Drug Class, 2012 – 2024 (USD Million) 4.2.2 Ciprofloxacin 4.2.2.1 U.S. Ciprofloxacin for Bacterial Conjunctivitis Market Revenue, 2012 – 2024 (USD Million) 4.2.3 Ofloxacin 4.2.3.1 U.S. Ofloxacin for Bacterial Conjunctivitis Market Revenue, 2012 – 2024 (USD Million) 4.2.4 Levofloxacin 4.2.4.1 U.S. Levofloxacin for Bacterial Conjunctivitis Market Revenue, 2012 – 2024 (USD Million) 4.2.5 Moxifloxacin 4.2.5.1 U.S. Moxifloxacin for Bacterial Conjunctivitis Market Revenue, 2012 – 2024 (USD Million) 4.2.6 Gatifloxacin 4.2.6.1 U.S. Gatifloxacin for Bacterial Conjunctivitis Market Revenue, 2012 – 2024 (USD Million) 4.2.7 Besifloxacin 4.2.7.1 U.S. Besifloxacin for Bacterial Conjunctivitis Market Revenue, 2012 – 2024 (USD Million) 4.3 Aminoglycosides 4.3.1 Aminoglycosides for Bacterial Conjunctivitis Market Revenue, by Drug Class, 2012 – 2024 (USD Million) 4.3.2 Tobramycin Persistence Market Research 8

9. Global U.s Bacterial Conjunctivitis Drugs Market - Future market size in the U.S. is expected to grow (2024) 4.3.2.1 U.S. Tobramycin for Bacterial Conjunctivitis Market Revenue, 2012 – 2024 (USD Million) 4.3.3 Gentamycin 4.3.3.1 U.S. Gentamycin for Bacterial Conjunctivitis Market Revenue, 2012 – 2024 (USD Million) 4.4 Macrolides 4.4.1 Macrolides for Bacterial Conjunctivitis Market Revenue, by Drug Class, 2012 – 2024 (USD Million) 4.4.2 Erythromycin 4.4.2.1 U.S. Erythromycin for Bacterial Conjunctivitis Market Revenue, 2012 – 2024 (USD Million) 4.4.3 Azithromycin 4.4.3.1 U.S. Azithromycin for Bacterial Conjunctivitis Market Revenue, 2012 – 2024 (USD Million) 4.5 Others (Bacitracin, Doxycycline, Polymyxin, and Fusidic Acid) 4.5.1.1 U.S. Others Market Revenue, by Bacterial Conjunctivitis, 2012 – 2024 (USD Million) Chapter 5 U.S. Bacterial Conjunctivitis Drugs Market, Pipeline Assessment 5.1 Overview 5.2 Vancomycin Ophthalmic Ointment 5.2.1 U.S. Vancomycin Ophthalmic Ointment for Bacterial Conjunctivitis Market Revenue, 2019 – 2024 (USD Million) 5.3 Early Stage (Phase I and Phase II trials) – Tabular Representation Chapter 6 Recommendations Chapter 7 Company Profiles 7.1 Actavis plc (now Allergan plc) 7.1.1 Company Overview 7.1.2 Financial Overview 7.1.3 Product Portfolio 7.1.4 Business Strategies 7.1.5 Recent Developments 7.2 Akorn, Inc. Persistence Market Research 9

10. Global U.s Bacterial Conjunctivitis Drugs Market - Future market size in the U.S. is expected to grow (2024) 7.2.1 Company Overview 7.2.2 Financial Overview 7.2.3 Product Portfolio 7.2.4 Business Strategies 7.2.5 Recent Developments 7.3 Bayer AG 7.3.1 Company Overview 7.3.2 Financial Overview 7.3.3 Product Portfolio 7.3.4 Business Strategies 7.3.5 Recent Developments 7.4 F. Hoffmann-La Roche Ltd. 7.4.1 Company Overview 7.4.2 Financial Overview 7.4.3 Product Portfolio 7.4.4 Business Strategies 7.4.5 Recent Developments 7.5 Merck & Co., Inc. 7.5.1 Company Overview 7.5.2 Financial Overview 7.5.3 Product Portfolio 7.5.4 Business Strategies 7.5.5 Recent Developments 7.6 Novartis AG 7.6.1 Company Overview 7.6.2 Financial Overview 7.6.3 Product Portfolio 7.6.4 Business Strategies 7.6.5 Recent Developments 7.7 Perrigo Company plc 7.7.1 Company Overview 7.7.2 Financial Overview 7.7.3 Product Portfolio 7.7.4 Business Strategies 7.7.5 Recent Developments Persistence Market Research 10

11. Global U.s Bacterial Conjunctivitis Drugs Market - Future market size in the U.S. is expected to grow (2024) 7.8 Pfizer, Inc. 7.8.1 Company Overview 7.8.2 Financial Overview 7.8.3 Product Portfolio 7.8.4 Business Strategies 7.8.5 Recent Developments 7.9 Santen Pharmaceutical Co., Ltd. 7.9.1 Company Overview 7.9.2 Financial Overview 7.9.3 Product Portfolio 7.9.4 Business Strategies 7.9.5 Recent Developments 7.10 Valeant Pharmaceuticals International, Inc. 7.10.1 Company Overview 7.10.2 Financial Overview 7.10.3 Product Portfolio 7.10.4 Business Strategies 7.10.5 Recent Developments List of Tables TABLE 1 Market Snapshot: U.S. Bacterial Conjunctivitis Drugs Market TABLE 2 Upcoming Patents Expiration of Branded Bacterial Conjunctivitis Drugs and Competing Companies of Generic Products TABLE 3 List of Ciprofloxacin API Manufacturers TABLE 4 List of Ofloxacin API Manufacturers TABLE 5 List of Levofloxacin API Manufacturers TABLE 6 List of Moxifloxacin API Manufacturers TABLE 7 List of Gatifloxacin API Manufacturers TABLE 8 List of Besifloxacin API Manufacturers TABLE 9 List of Tobramycin API Manufacturers TABLE 10 List of Gentamycin API Manufacturers TABLE 11 List of Erythromycin API Manufacturers TABLE 12 List of Azithromycin API Manufacturers TABLE 13 List of Bacitracin API Manufacturers Persistence Market Research 11

12. Global U.s Bacterial Conjunctivitis Drugs Market - Future market size in the U.S. is expected to grow (2024) TABLE 14 List of Neomycin API Manufacturers TABLE 15 List of Fusidic Acid API Manufacturers TABLE 16 Recommended Dosages for Treatment of Bacterial Conjunctivitis TABLE 17 U.S. Bacterial Conjunctivitis Drugs Market Revenue, by Drug Class, 2012 – 2018 (USD Million) TABLE 18 U.S. Bacterial Conjunctivitis Drugs Market Revenue, by Drug Class, 2019 – 2024 (USD Million) TABLE 19 Fluoroquinolones for Bacterial Conjunctivitis Market Revenue, by Drug Class, 2012 – 2018 (USD Million) TABLE 20 Fluoroquinolones for Bacterial Conjunctivitis Market Revenue, by Drug Class, 2019 – 2024 (USD Million) TABLE 21 Aminoglycosides for Bacterial Conjunctivitis Market Revenue, by Drug Class, 2012 – 2018 (USD Million) TABLE 22 Aminoglycosides for Bacterial Conjunctivitis Market Revenue, by Drug Class, 2019 – 2024 (USD Million) TABLE 23 Macrolides for Bacterial Conjunctivitis Market Revenue, by Drug Class, 2012 – 2018 (USD Million) TABLE 24 Macrolides for Bacterial Conjunctivitis Market Revenue, by Drug Class, 2019 – 2024 (USD Million) TABLE 25 Early Stage (Phase I and Phase II trials) – Tabular Representation TABLE 26 Actavis plc: Expenses & Revenue, 2011 – 2013 (USD Million) TABLE 27 Novartis AG: Expenses & Revenue, 2011 – 2013 (USD Million) List of Figures FIG. 1 U.S. Bacterial Conjunctivitis Drugs Market Segmentation FIG. 1 U.S. Bacterial Conjunctivitis Drugs Market, by Drug Class, 2013 (USD Million) FIG. 2 U.S. Bacterial Conjunctivitis Drugs Market: Drivers, and Restraints FIG. 3 Market Attractiveness Analysis: U.S. Bacterial Conjunctivitis Drugs Market, by Drug Class FIG. 4 Market Share Analysis: U.S. Bacterial Conjunctivitis Drugs Market, by Key Players, 2013 (Value %) FIG. 5 U.S. Ciprofloxacin for Bacterial Conjunctivitis Market Revenue, 2012 – 2024 (USD Million) FIG. 6 U.S. Ofloxacin for Bacterial Conjunctivitis Market Revenue, 2012 – 2024 (USD Million) Persistence Market Research 12

13. Global U.s Bacterial Conjunctivitis Drugs Market - Future market size in the U.S. is expected to grow (2024) FIG. 7 U.S. Levofloxacin for Bacterial Conjunctivitis Market Revenue, 2012 – 2024 (USD Million) FIG. 8 U.S. Moxifloxacin for Bacterial Conjunctivitis Market Revenue, 2012 – 2024 (USD Million) FIG. 9 U.S. Gatifloxacin for Bacterial Conjunctivitis Market Revenue, 2012 – 2024 (USD Million) FIG. 10 U.S. Besifloxacin for Bacterial Conjunctivitis Market Revenue, 2012 – 2024 (USD Million) FIG. 11 U.S. Tobramycin for Bacterial Conjunctivitis Market Revenue, 2012 – 2024 (USD Million) FIG. 12 U.S. Gentamycin for Bacterial Conjunctivitis Market Revenue, 2012 – 2024 (USD Million) FIG. 13 U.S. Erythromycin for Bacterial Conjunctivitis Market Revenue, 2012 – 2024 (USD Million) FIG. 14 U.S. Azithromycin for Bacterial Conjunctivitis Market Revenue, 2012 – 2024 (USD Million) FIG. 15 U.S. Others Market Revenue, by Bacterial Conjunctivitis, 2012 – 2024 (USD Million) FIG. 16 U.S. Vancomycin Ophthalmic Ointment for Bacterial Conjunctivitis Market Revenue, 2019 – 2024 (USD Million) FIG. 17 Actavis plc.: Annual Revenue, 2011 – 2013 (USD Million) FIG. 18 Akorn, Inc.: Annual Revenue, 2011 – 2013 (USD million) FIG. 19 Bayer AG (Bayer HealthCare): Annual Revenue, 2011 – 2013 (USD Million) FIG. 20 F. Hoffmann-La Roche Ltd.: Annual Revenue, 2011 – 2013 (USD Million) FIG. 21 Annual Revenue: Merck & Co., Inc., 2011 – 2013 (USD Million) FIG. 22 Novartis AG: Annual Revenue, 2011 – 2013 (USD Million) FIG. 23 Perrigo Company plc.: Annual Revenue, 2011 – 2013 (USD Million) FIG. 24 Pfizer, Inc.: Annual Revenue, 2011 – 2013 (USD Million) FIG. 25 Santen Pharmaceutical Co., Ltd.: Annual Revenue, 2011 – 2013 (USD million) FIG. 26 Valeant Pharmaceuticals International, Inc.: Annual Revenue, 2011 – 2013 (USD Million) Persistence Market Research 13

14. Global U.s Bacterial Conjunctivitis Drugs Market - Future market size in the U.S. is expected to grow (2024) About Us: Persistence Market Research (PMR) is a full-service market intelligence firm specializing in syndicated research, custom research, and consulting services. PMR boasts market research expertise across the Healthcare, Chemicals and Materials, Technology and Media, Energy and Mining, Food and Beverages, Semiconductor and Electronics, Consumer Goods, and Shipping and Transportation industries. The company draws from its multi-disciplinary capabilities and high-pedigree team of analysts to share data that precisely corresponds to clients’ business needs. PMR stands committed to bringing more accuracy and speed to clients’ business decisions. From ready-to-purchase market research reports to customized research solutions, PMR’s engagement models are highly flexible without compromising on its deep-seated research values. Contact Us: Persistence Market Research 305 Broadway 7th Floor, New York City, NY 10007, United States, USA - Canada Toll Free: +1 800-961-0353 Email: sales@persistencemarketresearch.com Web: http://www.persistencemarketresearch.com Persistence Market Research 14